Provectus Biopharmaceuticals, Inc. (PVCT)
| Market Cap | 29.27M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.56M |
| Shares Out | 393.50M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 23 |
| Last Price | $0.0730 |
| Previous Close | $0.0750 |
| Change ($) | -0.0020 |
| Change (%) | -2.67% |
| Day's Open | 0.0749 |
| Day's Range | 0.0657 - 0.0749 |
| Day's Volume | 436,448 |
| 52-Week Range | 0.03 - 0.1 |
News
KNOXVILLE, TN, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center (Moffitt) has released a manuscript preprint describing how investiga...
About PVCT
Provectus Biopharmaceuticals, a clinical-stage biotechnology company, engages in developing drugs based on halogenated xanthenes for oncology, hematology, and dermatology indications. Its prescription drug candidates include PV-10, which is in Phase Ib/II study for metastatic melanoma; Phase I study for hepatocellular carcinoma and other solid tumors metastatic to the liver; and non-clinical assessment of pediatric cancer tumor cell. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis... [Read more...]
| Industry Biotechnology | Founded 2002 |
| Stock Exchange OTCMKTS | Ticker Symbol PVCT |